Articles

QMSR aligns the rules. The bigger change is how inspections will feel.

Everyone is discussing the ISO 13485 alignment. The more consequential shift is from QSIT’s four subsystems to following a product risk across the device lifecycle.

3 min read

Everyone is talking about FDA’s new Quality Management System Regulation and the alignment with ISO 13485. That part is true. But the piece I find most interesting is how inspections may feel in practice.

What QSIT trained everyone to expect

For many years device inspections largely followed the QSIT model. Investigators evaluated four major subsystems: management controls, design controls, CAPA, and production and process controls. Many device quality systems were organised around those areas, because everyone understood how FDA inspections typically flowed.

Under the new inspection program supporting QMSR, investigators still evaluate defined quality system areas, but the program places stronger emphasis on risk and on the connections between processes across the device lifecycle.

In practice that means an investigator may begin with a product risk and follow the processes that control that risk across the system. A design risk might lead to supplier controls, then process validation, and later complaint handling or corrective action, if those processes are connected to the same issue.

Vioela’s note: For anyone who wants to read the source: the inspection approach is set out in FDA’s Compliance Program 7382.850, which took over from QSIT when the new regulation took effect on February 2, 2026. Read it the way an investigator does. It tells them how to choose what to look at, and pre-inspection information such as the adverse event reports you have filed feeds that choice. In other words, the inspection starts before anyone arrives, with data you sent the agency yourself.

Why this feels familiar to drug investigators

During drug inspections we were often assigned to combination product facilities alongside device investigators. The drug investigator focused on the drug manufacturing systems while the device investigator evaluated the device quality system, and the inspection naturally required understanding how both sides intersected within the same product lifecycle.

Because of that experience, the lifecycle perspective emphasised under QMSR feels familiar to me.

In my opinion, investigators who have spent much of their careers inspecting drug manufacturing systems may find this approach intuitive, since drug inspections have long followed process flow and risk across the lifecycle of a product. For investigators accustomed to the traditional QSIT subsystem structure, the shift may simply require a slightly different way of navigating through the system.

What changes for industry

The preparation question shifts slightly.

It is no longer only about organising documentation around traditional subsystems. It is about clearly demonstrating how risk is controlled across the entire device lifecycle.

One practical note for fellow consultants: this may also be the year to increase the regulatory reading budget. Between ISO and AAMI, the QMSR supporting materials are not exactly free.

Vioela’s note: The change with the most practical bite gets the least attention. Under the old regulation, FDA investigators did not get to read your management review minutes, internal audit reports or supplier audit reports. The new regulation does not carry that exception forward, and FDA has said it intends to review those records. Many of them were written candidly, for an internal audience, on the assumption that the agency would never see them. Read your last two years of them now with an outsider’s eye. What matters is not that problems were recorded. It is whether each one was followed through.

Adapted from a post first published on LinkedIn.